{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:50:10Z","timestamp":1790704210781,"version":"4.1.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00280-019-03936-w","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T02:04:11Z","timestamp":1567562651000},"page":"1157-1166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs"],"prefix":"10.1007","volume":"84","author":[{"given":"Vinay","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonu Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2395-6086","authenticated-orcid":false,"given":"Malkhey","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,4]]},"reference":[{"key":"3936_CR1","first-page":"723","volume-title":"The cell A molecular approach","author":"GM Cooper","year":"2016","unstructured":"Cooper GM, Hausman RE (2016) Chapter 19 Cancer. In: Cooper GM, Hausman RE (eds) The cell A molecular approach. Sunnderland, Sinauer Associates USA Inc, Massachusetts, pp 723\u2013726"},{"issue":"5","key":"3936_CR2","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.talanta.2011.08.034","volume":"85","author":"S Nussbaumera","year":"2011","unstructured":"Nussbaumera S, Bonnabrya P, Veuthey JL, Fleury-Souveraina S (2011) Analysis of anticancer drugs; a review. Talanta 85(5):2265\u20132289","journal-title":"Talanta"},{"issue":"3","key":"3936_CR3","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/cancers2031717","volume":"2","author":"K Miura","year":"2010","unstructured":"Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T et al (2010) 5-FU metabolism in cancer and orally-administrable 5-FU drugs. Cancers 2(3):1717\u20131730","journal-title":"Cancers"},{"issue":"4","key":"3936_CR4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/A:1006416410198","volume":"18","author":"JL Grem","year":"2000","unstructured":"Grem JL (2000) 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 18(4):299\u2013313","journal-title":"Invest New Drugs"},{"issue":"3","key":"3936_CR5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00280-011-1666-0","volume":"68","author":"P-Y Cordier","year":"2011","unstructured":"Cordier P-Y, Nau A, Ciccolini J, Oliver M, Mercier C, Lacarelle B, Peytel E (2011) 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases. Cancer Chemother Pharmacol 68(3):823\u2013826","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"3936_CR6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jcp.1041040305","volume":"104","author":"RM Wohlhueter","year":"1980","unstructured":"Wohlhueter RM, Scott MR, Plagemann PG (1980) Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol 104(3):309\u2013319","journal-title":"J Cell Physiol"},{"issue":"8","key":"3936_CR7","first-page":"2203","volume":"47","author":"G Heggie","year":"1987","unstructured":"Heggie G, Sommadossi J-P, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Can Res 47(8):2203\u20132206","journal-title":"Can Res"},{"issue":"5","key":"3936_CR8","first-page":"330","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Cancer 3(5):330","journal-title":"Cancer"},{"issue":"18","key":"3936_CR9","first-page":"4243","volume":"53","author":"JA Houghton","year":"1993","unstructured":"Houghton JA, Morton CL, Adkins DA, Rahman A (1993) Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells. Can Res 53(18):4243\u20134250","journal-title":"Can Res"},{"issue":"19","key":"3936_CR10","doi-asserted-by":"crossref","first-page":"9802","DOI":"10.1016\/S0021-9258(19)68695-3","volume":"256","author":"DW Kufe","year":"1981","unstructured":"Kufe DW, Major PP (1981) 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem 256(19):9802\u20139805","journal-title":"J Biol Chem"},{"issue":"2","key":"3936_CR11","first-page":"468","volume":"21","author":"RI Glazer","year":"1982","unstructured":"Glazer RI, Lloyd LS (1982) Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol Pharmacol 21(2):468\u2013473","journal-title":"Mol Pharmacol"},{"issue":"1","key":"3936_CR12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00299864","volume":"17","author":"R Kanamaru","year":"1986","unstructured":"Kanamaru R, Kakuta H, Sato T, Ishioka C, Wakui A (1986) The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L-1210 cells in vitro. Cancer Chemother Pharmacol 17(1):43\u201346","journal-title":"Cancer Chemother Pharmacol"},{"issue":"26","key":"3936_CR13","doi-asserted-by":"crossref","first-page":"8599","DOI":"10.1021\/bi00400a016","volume":"26","author":"DV Santi","year":"1987","unstructured":"Santi DV, Hardy LW (1987) Catalytic mechanism and inhibition of tRNA (uracil-5-) methyltransferase: evidence for covalent catalysis. Biochemistry 26(26):8599\u20138606","journal-title":"Biochemistry"},{"key":"3936_CR14","doi-asserted-by":"crossref","unstructured":"Randerath K, Tseng WC, Harris JS, Lu LJW (1983) Specific effects of 5-fluoropyrimidines and 5-azapyrimidines on modification of the 5 position of pyrimidines, in particular the synthesis of 5-methyluracil and 5-methylcytosine in nucleic acids. Book series (RECENTCANCER, vol 84) Modified Nucleosides and Cancer, pp 283\u2013297","DOI":"10.1007\/978-3-642-81947-6_22"},{"issue":"3","key":"3936_CR15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/0006-291X(74)90601-9","volume":"57","author":"H Sommer","year":"1974","unstructured":"Sommer H, Santi DV (1974) Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2\u2032-deoxyuridylate and methylenetetrahydrofolate. Biochem Biophys Res Commun 57(3):689\u2013695","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"3936_CR16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1021\/bi00700a012","volume":"13","author":"DV Santi","year":"1974","unstructured":"Santi DV, McHenry CS, Sommer H (1974) Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13(3):471\u2013481","journal-title":"Biochemistry"},{"issue":"10","key":"3936_CR17","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0006-2952(96)00035-4","volume":"51","author":"GW Aherne","year":"1996","unstructured":"Aherne GW, Hardcastle A, Raynaud F, Jackman AL (1996) Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a non-polyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. Biochem Pharmacol 51(10):1293\u20131301","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"3936_CR18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF00686631","volume":"35","author":"B Mitrovski","year":"1994","unstructured":"Mitrovski B, Pressacco J, Mandelbaum S, Erlichman C (1994) Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells. Cancer Chemother Pharmacol 35(2):109\u2013114","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"3936_CR19","first-page":"3262","volume":"50","author":"LH Matherly","year":"1990","unstructured":"Matherly LH, Czajkowski CA, Muench SP, Psiakis JT (1990) Role for cytosolic folate-binding proteins in the compartmentation of endogenous tetrahydrofolates and the 5-formyl tetrahydrofolate-mediated enhancement of 5-fluoro-2\u2032-deoxyuridine antitumor activity in vitro. Can Res 50(11):3262\u20133269","journal-title":"Can Res"},{"issue":"19","key":"3936_CR20","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/jnci\/80.19.1560","volume":"80","author":"JG Park","year":"1988","unstructured":"Park JG, Collins JM, Gazdar AF, Allegra CJ, Steinberg SM, Greene RF et al (1988) Enhancement of fluorinated pyrimidine induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Natl Cancer Inst 80(19):1560\u20131564","journal-title":"J Natl Cancer Inst"},{"key":"3936_CR21","unstructured":"Nadal J, Van GC, Pinedo H, Peters G (1988) In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma. Biomed Pharmacother 42(6):387\u2013393"},{"issue":"10","key":"3936_CR22","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1016\/S0021-9258(17)34838-X","volume":"253","author":"BJ Dolnick","year":"1978","unstructured":"Dolnick BJ, Cheng YC (1978) Human thymidylate synthetase. II. Derivatives of pteroylmono- and -polyglutamates as substrates and inhibitors. J Biol Chem 253(10):3563\u20133567","journal-title":"J Biol Chem"},{"issue":"2","key":"3936_CR23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0006-2952(89)90046-4","volume":"38","author":"S Radparvar","year":"1988","unstructured":"Radparvar S, Houghton PJ, Houghton JA (1988) Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2\u2032-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol 38(2):335\u2013342","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"3936_CR24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1365-2125.1999.00010.x","volume":"48","author":"AA Adjei","year":"2001","unstructured":"Adjei AA (2001) A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol 48(3):265\u2013277","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3936_CR25","first-page":"1239","volume":"55","author":"T Spector","year":"1995","unstructured":"Spector T, Cao S, Rustum YM, Harrington JA, Porter DJ (1995) Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. Can Res 55(6):1239\u20131241","journal-title":"Can Res"},{"issue":"8","key":"3936_CR26","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","volume":"34","author":"M Miwa","year":"1998","unstructured":"Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34(8):1274\u20131281","journal-title":"Eur J Cancer"},{"issue":"8","key":"3936_CR27","first-page":"2313","volume":"62","author":"D Cao","year":"2002","unstructured":"Cao D, Russell RL, Zhang D, Leffert JJ, Pizzorno G (2002) Uridine phosphorylase (\u2212\/\u2212) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Can Res 62(8):2313\u20132317","journal-title":"Can Res"},{"issue":"8","key":"3936_CR28","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","volume":"19","author":"PM Hoff","year":"2001","unstructured":"Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Maroun MK et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19(8):2282\u20132292","journal-title":"J Clin Oncol"},{"key":"3936_CR29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-1-59259-725-3_3","volume-title":"Antifolate Drugs in Cancer Therapy","author":"Richard Gorlick","year":"1999","unstructured":"Gorlick R, Bertino JR (1999) Clinical pharmacology and resistance to dihydrofolate reductase inhibitors. In: Jackman AL (ed) Antifolate Drugs in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ"},{"issue":"4","key":"3936_CR30","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0021-9258(19)69863-7","volume":"256","author":"E Cadman","year":"1981","unstructured":"Cadman E, Heimer R, Benz C (1981) The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem 256(4):1695\u20131704","journal-title":"J Biol Chem"},{"issue":"23","key":"3936_CR31","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/jnci\/90.23.1810","volume":"90","author":"N Wolmark","year":"1998","unstructured":"Wolmark N, Bryant J, Smith R, Jean G, Allegra C, Hyams D et al (1998) Adjuvant 5 fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: national Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 90(23):1810\u20131816","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"3936_CR32","first-page":"2602","volume":"56","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A et al (1996) Antitumor activity of 1\u00a0m Tegafur-0.4\u00a0m 5-chloro-2,4-dihydroxypyridine-1\u00a0m potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56(11):2602\u20132606","journal-title":"Cancer Res"},{"issue":"5","key":"3936_CR33","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5):548\u2013557","journal-title":"Anticancer Drugs"},{"issue":"17","key":"3936_CR34","first-page":"4004","volume":"53","author":"T Shirasaka","year":"1993","unstructured":"Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Can Res 53(17):4004\u20134009","journal-title":"Can Res"},{"issue":"3","key":"3936_CR35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s10147-003-0330-z","volume":"8","author":"K Omura","year":"2003","unstructured":"Omura K (2003) Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 8(3):132\u2013138","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"3936_CR36","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMra040958","volume":"352","author":"JA Meyerhardt","year":"2005","unstructured":"Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352(5):476\u2013487","journal-title":"N Engl J Med"},{"issue":"26","key":"3936_CR37","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","volume":"352","author":"C Twelves","year":"2005","unstructured":"Twelves C, Wong A, Nowacki MP, Abt M, Burris H, Carrato A et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352(26):2696\u20132704","journal-title":"N Engl J Med"},{"key":"3936_CR38","first-page":"871","volume":"6","author":"P Wigmore","year":"2010","unstructured":"Wigmore P, Mustafa S, El-Bettagy M, Lyons L, Umka J, Bennett G (2010) Effects of 5-FU. Adv Exp Med Biol 6:871\u2013881","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"3936_CR39","first-page":"23","volume":"12","author":"RB Diasio","year":"1998","unstructured":"Diasio RB (1998) The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Cancer Network 12(10):23\u201327","journal-title":"Cancer Network"},{"key":"3936_CR40","doi-asserted-by":"crossref","unstructured":"Alsanosi SM, Skiffington C, Padmanabhan S (2014) Chapter 17\u2014pharmacokinetic pharmacogenomics. Handbook Pharmacogenomics Stratified Med 341-364","DOI":"10.1016\/B978-0-12-386882-4.00017-7"},{"issue":"2","key":"3936_CR41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0163-7258(90)90080-L","volume":"48","author":"GC Daher","year":"1990","unstructured":"Daher GC, Harris BE, Diasio RB (1990) Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 48(2):189\u2013222","journal-title":"Pharmacol Ther"},{"issue":"10","key":"3936_CR42","first-page":"2672","volume":"5","author":"RB Diasio","year":"1999","unstructured":"Diasio RB, Johnson MR (1999) Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 5(10):2672\u20132673","journal-title":"Clin Cancer Res"},{"issue":"11","key":"3936_CR43","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","volume":"12","author":"MC Etienne","year":"1994","unstructured":"Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Schneider NR et al (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12(11):2248\u20132253","journal-title":"J Clin Oncol"},{"issue":"22","key":"3936_CR44","first-page":"5433","volume":"53","author":"Z Lu","year":"1993","unstructured":"Lu Z, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Can Res 53(22):5433\u20135438","journal-title":"Can Res"},{"issue":"4","key":"3936_CR45","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM198507253130407","volume":"313","author":"M Tuchman","year":"1985","unstructured":"Tuchman M, Stoeckeler JS, Kiang DT, O\u2019Dea RF, Ramnaraine ML, Mirkin BL (1985) Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313(4):245\u2013249","journal-title":"N Engl J Med"},{"issue":"1","key":"3936_CR46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1172\/JCI113308","volume":"81","author":"RB Diasio","year":"1988","unstructured":"Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Investig 81(1):47\u201351","journal-title":"J Clin Investig"},{"key":"3936_CR47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biopha.2018.05.117","volume":"105","author":"S Pathania","year":"2018","unstructured":"Pathania S, Bhatia R, Baldi A, Singh R, Rawal RK (2018) Drug metabolizing enzymes and their inhibitor\u2019s role in cancer resistance. Biomed Pharmacol 105:53\u201365","journal-title":"Biomed Pharmacol"},{"issue":"10","key":"3936_CR48","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0165-6147(00)89065-3","volume":"16","author":"FJ Gonzalez","year":"1995","unstructured":"Gonzalez FJ, Fernander-Salguero P (1995) Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol Sci 16(10):325\u2013327","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"3936_CR49","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/0163-7258(80)90079-0","volume":"8","author":"C Wasternack","year":"1980","unstructured":"Wasternack C (1980) Degradation of pyrimidines and pyrimidine analogs\u2014pathways and mutual influences. Pharmacol Ther 8(3):629\u2013651","journal-title":"Pharmacol Ther"},{"issue":"3","key":"3936_CR50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0009-8981(84)90206-7","volume":"140","author":"J Bakkere","year":"1984","unstructured":"Bakkere J, De Abreu R, Sengers R, Gabre\u00ebls F, Maas J, Renier W (1984) Elevated urine, blood and cerebrospinal fluid levels of uracil and thymine in a child with dihydrothymine dehydrogenase deficiency. Clin Chim Acta 140(3):247\u2013256","journal-title":"Clin Chim Acta"},{"issue":"1","key":"3936_CR51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF01799339","volume":"13","author":"M Brockstedt","year":"1990","unstructured":"Brockstedt M, Jakobs C, Smit LM, Gennip AH, Berger R (1990) A new case of dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis 13(1):121\u2013124","journal-title":"J Inherit Metab Dis"},{"issue":"16","key":"3936_CR52","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","volume":"16","author":"D Meulendijks","year":"2015","unstructured":"Meulendijks D, Henricks LM, Sonke GSJ, Deenem MJ, Froehlich TK, Amstutz U (2015) Clinical relevance of DPYD variants c.1679T > G, c.1236G > A\/HapB3, and c.1601G > A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16(16):1639\u20131650","journal-title":"Lancet Oncol"},{"issue":"11 Part 1","key":"3936_CR53","first-page":"5405","volume":"45","author":"FN Naguib","year":"1985","unstructured":"Naguib FN, Kouni MH, Cha S (1985) Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Research 45(11 Part 1):5405\u20135412","journal-title":"Cancer Research"},{"issue":"1","key":"3936_CR54","first-page":"197","volume":"50","author":"B Harris","year":"1990","unstructured":"Harris B, Song R, Diasio R (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Can Res 50(1):197\u2013201","journal-title":"Can Res"},{"issue":"1","key":"3936_CR55","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/1471-2407-8-386","volume":"8","author":"K Uchida","year":"2008","unstructured":"Uchida K, Danenberg PV, Danenberg KD, Grem JL (2008) Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. BMC Cancer 8(1):386","journal-title":"BMC Cancer"},{"issue":"3","key":"3936_CR56","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3892\/mco.2014.267","volume":"2","author":"T Yamashita","year":"2013","unstructured":"Yamashita T, Kato K, Long NK, Makita H, Yonemoto K, Iida K et al (2013) Effects of smoking and alcohol consumption on 5-fluorouracil-related metabolic enzymes in oral squamous cell carcinoma. Mol Clin Oncol 2(3):429\u2013434","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"3936_CR57","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/FTD.0000000000000109","volume":"37","author":"JG Shin","year":"2015","unstructured":"Shin JG, Kang T, Cheong H, Shin H, Park H, Na H et al (2015) Determination of DPYD enzyme activity in korean population. Ther Drug Monit 37(2):147\u2013151","journal-title":"Ther Drug Monit"},{"issue":"2","key":"3936_CR58","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4103\/0973-1482.148685","volume":"12","author":"G-Y Li","year":"2016","unstructured":"Li G-Y, Duan J-F, Li W-J, Liu T (2016) DPYD*2A\/*5A\/*9A and UGT1A1*6\/*28 polymorphisms in Chinese colorectal cancer patients. J Cancer Res Therapeutics 12(2):782","journal-title":"J Cancer Res Therapeutics"},{"issue":"6","key":"3936_CR59","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/clpt.2013.172","volume":"94","author":"K Caudle","year":"2013","unstructured":"Caudle K, Thorn C, Klein T, Swen J, McLeod H, Diasio R, Schwab M (2013) Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Therapeutics 94(6):640\u2013645","journal-title":"Clin Pharmacol Therapeutics"},{"issue":"9","key":"3936_CR60","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/bjc.2017.289","volume":"117","author":"A Ruzzo","year":"2017","unstructured":"Ruzzo A, Grazianp F, Galli F, Galli FR, Lonardi S, Ranzoni M et al (2017) Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. Br J Cancer 117(9):1269","journal-title":"Br J Cancer"},{"issue":"1","key":"3936_CR61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1258\/000456303321016150","volume":"40","author":"AB Kuilenburg","year":"2003","unstructured":"Kuilenburg AB, Abreu RA, Gennip AH (2003) Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem 40(1):41\u201345","journal-title":"Ann Clin Biochem"},{"issue":"238","key":"3936_CR62","first-page":"238","volume":"60","author":"V Sulzyc-Bielicka","year":"2008","unstructured":"Sulzyc-Bielicka V, Binczak-Kuleta A, Pioch W, Kladny J, Gziut K, Bielicki D et al (2008) 5-Fluorouracil toxicity-attributable IVS14\u2009+\u20091G\u2009>\u2009A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients. Pharmacol Rep 60(238):238\u2013242","journal-title":"Pharmacol Rep"},{"issue":"2","key":"3936_CR63","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00008571-200203000-00007","volume":"12","author":"L Mattison","year":"2002","unstructured":"Mattison L, Johnson M, Diasio RB (2002) A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenet Genomics 12(2):133\u2013144","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"3936_CR64","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MJT.0b013e31829e8516","volume":"22","author":"Y Baskin","year":"2015","unstructured":"Baskin Y, Amirfallah A, Unal OU, Calibasi G, Oztop I (2015) Dihydropyrimidine dehydrogenase 85T\u2009>\u2009C mutation is associated with ocular toxicity of 5-fluorouracil: a case report. Am J Ther 22(2):36\u201339","journal-title":"Am J Ther"},{"issue":"6","key":"3936_CR65","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00008571-199412000-00002","volume":"4","author":"G Milano","year":"1994","unstructured":"Milano G, Etienne MC (1994) Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenet Genomics 4(6):301\u2013306","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"3936_CR66","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/FTD.0b013e318290acd2","volume":"35","author":"LK Teh","year":"2013","unstructured":"Teh LK, Hamzah S, Hashim H, Bannur Z, Zakaria ZA, Hasbullani Z (2013) Potential of Dihydropyrimidine Dehydrogenase Genotypes in Personalizing 5-Fluorouracil Therapy Among Colorectal Cancer Patients. Ther Drug Monit 35(5):624\u2013630","journal-title":"Ther Drug Monit"},{"issue":"16","key":"3936_CR67","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1158\/1078-0432.CCR-04-1784","volume":"11","author":"K Seck","year":"2005","unstructured":"Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N et al (2005) Analysis of the DPYD gene implicated in 5-Fluorouracil catabolism in a cohort of caucasian individuals. Clin Cancer Res 11(16):5886\u20135892","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3936_CR68","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2710.2008.00898.x","volume":"33","author":"YF He","year":"2008","unstructured":"He YF, Wei W, Zhang X, Li YHS, Wang FH, Jiang WQ (2008) Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in chinese cancer patients. J Clin Pharm Ther 33(3):307\u2013314","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"3936_CR69","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4103\/0971-6866.124382","volume":"19","author":"HH Khallaf","year":"2013","unstructured":"Khallaf HH, He M, Wittenauer A, Woolley EE, Cunto M, Pervaiz MA (2013) An incidental case of dihydropyrimidine dehydrogenase deficiency: one case, multiple challenges. Indian J Hum Genetics 19(4):483","journal-title":"Indian J Hum Genetics"},{"issue":"12","key":"3936_CR70","first-page":"4705","volume":"6","author":"AB Kuilenburg","year":"2000","unstructured":"Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Lenthe HV, Abreu RA et al (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6(12):4705\u20134712","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3936_CR71","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3816\/CCC.2004.n.018","volume":"4","author":"H Ezzeldin","year":"2004","unstructured":"Ezzeldin H, Diasio R (2004) Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 4(3):181\u2013189","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"3936_CR72","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/bbrc.2000.2593","volume":"271","author":"E Collie-Duguid","year":"2000","unstructured":"Collie-Duguid E, Johnston SJ, Powrie R, Milano G, Etienne MC, Rochat B et al (2000) Cloning and initial characterization of the human DPYD gene promoter. Biochem Biophys Res Commun 271(1):28\u201335","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"3936_CR73","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.10599","volume":"101","author":"AB Kuilenburg","year":"2002","unstructured":"Kuilenburg AB, Meinsma R, Zoetekouw L, Gennip AH (2002) Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14\u2009+\u20091g\u2009>\u2009a mutation. Int J Cancer 101(3):253\u2013258","journal-title":"Int J Cancer"},{"issue":"4","key":"3936_CR74","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14622416.3.4.485","volume":"3","author":"L Mattison","year":"2002","unstructured":"Mattison L, Soong R, Diasio RB (2002) Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 3(4):485\u2013492","journal-title":"Pharmacogenomics"},{"issue":"12","key":"3936_CR75","first-page":"2999","volume":"4","author":"M Kouwaki","year":"1998","unstructured":"Kouwaki M, Hamajima N, Sumi S, Nonaka M, Sasaki M, Dobashi K et al (1998) Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin Cancer Res 4(12):2999\u20133004","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3936_CR76","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s004390050637","volume":"101","author":"P Vreken","year":"1997","unstructured":"Vreken P, Kuilenburg AB, Meinsma R, van Gennip AH (1997) Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum Genet 101(3):333\u2013338","journal-title":"Hum Genet"},{"key":"3936_CR77","doi-asserted-by":"crossref","unstructured":"Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G et al (2018) Dihydropyrimidine d\u00e9hydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks. Bull Cancer 105(4):397\u2013407","DOI":"10.1016\/j.bulcan.2018.02.001"},{"issue":"1","key":"3936_CR78","first-page":"83","volume":"24","author":"G Morrison","year":"1997","unstructured":"Morrison G, Bastian A, Dela Rosa T, Diasio RT (1997) Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Oncol Nurs Forum 24(1):83\u201388","journal-title":"Oncol Nurs Forum"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03936-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03936-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03936-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T10:44:48Z","timestamp":1664275488000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03936-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,4]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3936"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03936-w","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,4]]},"assertion":[{"value":"3 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors declare no conflicting interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}